vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and CONSTELLIUM SE (CSTM). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $2.2B, roughly 1.3× CONSTELLIUM SE). CONSTELLIUM SE runs the higher net margin — 5.1% vs -3.7%, a 8.8% gap on every dollar of revenue. Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $109.0M).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Constellium SE is an American-Swiss, French-based global manufacturer of aluminium rolled products, extruded products, and structural parts based on a large variety of advanced alloys. Constellium's C-TEC research center has been credited for advancing technology in the field of advanced aluminium alloy. Constellium primarily serves the aerospace, automotive, and packaging sectors. Large clients include Mercedes-Benz, Audi, BMW, Fiat Chrysler Automotive, Ford, Airbus, Boeing, and Bombardier.
BHC vs CSTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $2.2B |
| Net Profit | $-103.0M | $112.0M |
| Gross Margin | — | — |
| Operating Margin | 17.0% | 7.5% |
| Net Margin | -3.7% | 5.1% |
| Revenue YoY | 9.3% | — |
| Net Profit YoY | -205.1% | — |
| EPS (diluted) | $-0.30 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $2.2B | ||
| Q3 25 | $2.7B | $2.2B | ||
| Q2 25 | $2.5B | $2.1B | ||
| Q1 25 | $2.3B | $2.0B | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.4B | $1.9B | ||
| Q1 24 | $2.2B | — |
| Q4 25 | $-103.0M | $112.0M | ||
| Q3 25 | $179.0M | $88.0M | ||
| Q2 25 | $148.0M | $36.0M | ||
| Q1 25 | $-58.0M | $37.0M | ||
| Q4 24 | $98.0M | — | ||
| Q3 24 | $-85.0M | — | ||
| Q2 24 | $10.0M | $76.0M | ||
| Q1 24 | $-64.0M | — |
| Q4 25 | 17.0% | 7.5% | ||
| Q3 25 | 23.1% | 5.8% | ||
| Q2 25 | 17.5% | 2.7% | ||
| Q1 25 | 12.2% | 3.1% | ||
| Q4 24 | 21.8% | — | ||
| Q3 24 | 12.7% | — | ||
| Q2 24 | 16.2% | 5.4% | ||
| Q1 24 | 13.1% | — |
| Q4 25 | -3.7% | 5.1% | ||
| Q3 25 | 6.7% | 4.1% | ||
| Q2 25 | 5.8% | 1.7% | ||
| Q1 25 | -2.6% | 1.9% | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | -3.4% | — | ||
| Q2 24 | 0.4% | 3.9% | ||
| Q1 24 | -3.0% | — |
| Q4 25 | $-0.30 | $0.79 | ||
| Q3 25 | $0.48 | $0.62 | ||
| Q2 25 | $0.40 | $0.25 | ||
| Q1 25 | $-0.16 | $0.26 | ||
| Q4 24 | $0.24 | — | ||
| Q3 24 | $-0.23 | — | ||
| Q2 24 | $0.03 | $0.51 | ||
| Q1 24 | $-0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $120.0M |
| Total DebtLower is stronger | $20.8B | $1.9B |
| Stockholders' EquityBook value | $-554.0M | $952.0M |
| Total Assets | $26.4B | $5.4B |
| Debt / EquityLower = less leverage | — | 2.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $120.0M | ||
| Q3 25 | $1.3B | $122.0M | ||
| Q2 25 | $1.7B | $133.0M | ||
| Q1 25 | $1.1B | $118.0M | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $719.0M | — | ||
| Q2 24 | $595.0M | — | ||
| Q1 24 | $733.0M | — |
| Q4 25 | $20.8B | $1.9B | ||
| Q3 25 | $21.0B | $2.0B | ||
| Q2 25 | $21.7B | $2.0B | ||
| Q1 25 | $21.5B | $1.9B | ||
| Q4 24 | $21.6B | — | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | — | ||
| Q1 24 | $22.1B | — |
| Q4 25 | $-554.0M | $952.0M | ||
| Q3 25 | $-565.0M | $845.0M | ||
| Q2 25 | $-764.0M | $780.0M | ||
| Q1 25 | $-1.2B | $745.0M | ||
| Q4 24 | $-1.3B | — | ||
| Q3 24 | $-1.2B | — | ||
| Q2 24 | $-1.2B | $796.0M | ||
| Q1 24 | $-1.1B | — |
| Q4 25 | $26.4B | $5.4B | ||
| Q3 25 | $26.8B | $5.4B | ||
| Q2 25 | $27.3B | $5.4B | ||
| Q1 25 | $26.4B | $5.2B | ||
| Q4 24 | $26.5B | — | ||
| Q3 24 | $26.5B | — | ||
| Q2 24 | $26.5B | — | ||
| Q1 24 | $26.9B | — |
| Q4 25 | — | 2.00× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | 2.53× | ||
| Q1 25 | — | 2.56× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $218.0M |
| Free Cash FlowOCF − Capex | $403.0M | $109.0M |
| FCF MarginFCF / Revenue | 14.4% | 5.0% |
| Capex IntensityCapex / Revenue | 3.3% | 5.0% |
| Cash ConversionOCF / Net Profit | — | 1.95× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $159.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $218.0M | ||
| Q3 25 | $405.0M | $99.0M | ||
| Q2 25 | $289.0M | $114.0M | ||
| Q1 25 | $211.0M | $58.0M | ||
| Q4 24 | $601.0M | — | ||
| Q3 24 | $405.0M | — | ||
| Q2 24 | $380.0M | $138.0M | ||
| Q1 24 | $211.0M | — |
| Q4 25 | $403.0M | $109.0M | ||
| Q3 25 | $314.0M | $24.0M | ||
| Q2 25 | $190.0M | $37.0M | ||
| Q1 25 | $96.0M | $-11.0M | ||
| Q4 24 | $495.0M | — | ||
| Q3 24 | $334.0M | — | ||
| Q2 24 | $302.0M | $54.0M | ||
| Q1 24 | $129.0M | — |
| Q4 25 | 14.4% | 5.0% | ||
| Q3 25 | 11.7% | 1.1% | ||
| Q2 25 | 7.5% | 1.8% | ||
| Q1 25 | 4.2% | -0.6% | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 13.3% | — | ||
| Q2 24 | 12.6% | 2.8% | ||
| Q1 24 | 6.0% | — |
| Q4 25 | 3.3% | 5.0% | ||
| Q3 25 | 3.4% | 3.5% | ||
| Q2 25 | 3.9% | 3.7% | ||
| Q1 25 | 5.1% | 3.5% | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 3.2% | 4.3% | ||
| Q1 24 | 3.8% | — |
| Q4 25 | — | 1.95× | ||
| Q3 25 | 2.26× | 1.13× | ||
| Q2 25 | 1.95× | 3.17× | ||
| Q1 25 | — | 1.57× | ||
| Q4 24 | 6.13× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 38.00× | 1.82× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
CSTM
| Packaging Rolled Products | $1.0B | 46% |
| Automotive Rolled Products | $318.0M | 14% |
| Aerospace Rolled Products | $270.0M | 12% |
| Transportation Industry Defense And Other Rolled Products | $232.0M | 11% |
| Automotive Extruded Products | $220.0M | 10% |
| Other Extruded Products | $132.0M | 6% |
| Specialty And Other Thin Rolled Products | $22.0M | 1% |
